EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update

被引:78
作者
Babjuk, M. [1 ]
Oosterlinck, W. [2 ]
Sylvester, R. [3 ]
Kaasinen, E. [4 ]
Boehle, A. [5 ]
Palou-Redorta, J. [6 ]
Roupret, M. [7 ,8 ]
机构
[1] Charles Univ, Serv Urol, Hosp Motol, Segunda Fac Med, Prague, Czech Republic
[2] Hosp Univ Gante, Serv Urol, Gante, Belgium
[3] Oficina Cent Org Europea Invest & Tratamiento Can, Dept Bioestadist, Bruselas, Belgium
[4] Hosp Hyvinkaa, Serv Urol, Hyvinkaa, Finland
[5] Hosp HELIOS Agnes Karll, Serv Urol, Bad Schwartau, Germany
[6] Univ Autonoma Barcelona, Serv Urol, Fundacio Puigvert, E-08193 Barcelona, Spain
[7] Hosp Publ Paris, Serv Urol, Hosp Pitie Salpetriere, GHU Est, Paris, France
[8] Univ Paris 06, Fac Med Pierre & Marie Curie, Paris, France
来源
ACTAS UROLOGICAS ESPANOLAS | 2012年 / 36卷 / 07期
关键词
Bacillus Calmette-Guerin (BCG); Bladder cancer; Cystectomy; Cystoscopy; Diagnosis; European Association of Urology Guidelines; Follow-up; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR); Urothelial carcinoma; BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL CARCINOMA; IMMEDIATE POSTOPERATIVE INSTILLATION; INTRAVESICAL MITOMYCIN-C; LONG-TERM EFFICACY; IN-SITU; TRANSURETHRAL RESECTION; EUROPEAN ORGANIZATION; PHOTODYNAMIC DIAGNOSIS; PROPHYLACTIC TREATMENT;
D O I
10.1016/j.acuro.2011.12.001
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
Context and objective: To present the 2011 European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC). Evidence acquisition: Literature published between 2004 and 2010 on the diagnosis and treatment of NMIBC was systematically reviewed. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. Evidence synthesis: Tumours staged as Ta, T1, or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection (TUR) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TUR is essential for the patient's prognosis. Where the initial resection is incomplete or where a high-grade or T1 tumour is detected, a second TUR should be performed within 2-6 wk. In papillary tumours, the risks of both recurrence and progression may be estimated for individual patients using the scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups (separately for recurrence and progression) is pivotal to recommending adjuvant treatment. For patients with a low risk of tumour recurrence and progression, one immediate instillation of chemotherapy is recommended. Patients with an intermediate or high risk of recurrence and an intermediate risk of progression should receive one immediate instillation of chemotherapy followed by a minimum of 1 yr of bacillus Calmette-Guerin (BCG) intravesical immunotherapy or further instillations of chemotherapy. Papillary tumours with a high risk of progression and CIS should receive intravesical BCG for 1 yr. Cystectomy may be offered to the highest risk patients, and it is at least recommended in BCG failure patients. Conclusions: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. (C) 2011 AEU. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:389 / 402
页数:14
相关论文
共 73 条
[1]
[Anonymous], J UROL
[2]
Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial [J].
Au, JLS ;
Badalament, RA ;
Wientjes, MG ;
Young, DC ;
Warner, JA ;
Venema, PL ;
Pollifrone, DL ;
Harbrecht, JD ;
Chin, JL ;
Lerner, SP ;
Miles, BJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (08) :597-604
[3]
A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences [J].
Berrum-Svennung, Ingela ;
Granfors, Torvald ;
Jahnson, Staffan ;
Boman, Hans ;
Holmang, Sten .
JOURNAL OF UROLOGY, 2008, 179 (01) :101-105
[4]
Böhle A, 2004, UROLOGY, V63, P682, DOI 10.1016/j.urology.2003.11.049
[5]
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:: A formal meta-analysis of comparative studies on recurrence and toxicity [J].
Böhle, A ;
Jocham, D ;
Bock, PR .
JOURNAL OF UROLOGY, 2003, 169 (01) :90-95
[6]
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies [J].
Brausi, M ;
Collette, L ;
Kurth, K ;
van der Meijden, AP ;
Oosterlinck, W ;
Witjes, JA ;
Newling, D ;
Bouffioux, C ;
Sylvester, RJ .
EUROPEAN UROLOGY, 2002, 41 (05) :523-530
[7]
Prediction of Progression of Non-Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study [J].
Burger, Maximilian ;
van der Aa, Madelon N. M. ;
van Oers, Johanna M. M. ;
Brinkmann, Anke ;
van der Kwast, Theodorus H. ;
Steyerberg, Ewout C. ;
Stoehr, Robert ;
Kirkels, Wim J. ;
Denzinger, Stefan ;
Wild, Peter J. ;
Wieland, Wolf F. ;
Hofstaedter, Ferdinand ;
Hartmann, Arndt ;
Zwarthoff, Ellen C. .
EUROPEAN UROLOGY, 2008, 54 (04) :835-844
[8]
Center for Evidence Based Medicine, 2009, OXF CTR EV BAS MED L
[9]
Clinical Outcomes of Primary Bladder Carcinoma In Situ in a Contemporary Series [J].
Chade, Daher C. ;
Shariat, Shahrokh F. ;
Godoy, Guilherme ;
Savage, Caroline J. ;
Cronin, Angel M. ;
Bochner, Bernard H. ;
Donat, S. Machele ;
Herr, Harry W. ;
Dalbagni, Guido .
JOURNAL OF UROLOGY, 2010, 184 (01) :74-79
[10]
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin:: A prospective, randomized clinical trial [J].
Divrik, RT ;
Yildirim, Ü ;
Zorlu, F ;
Özen, H .
JOURNAL OF UROLOGY, 2006, 175 (05) :1641-1644